Frankfurt
03.04.25
15:29 Uhr
1,578 Euro
+0,040
+2,60 %
+2,60 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 359 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 300 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 321 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 429 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 126 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 01.10.24 | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 385 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| 18.09.24 | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 407 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen | |
| 18.07.24 | Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities | 357 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 15.05.24 | Advicenne Announces the Approval of All Resolutions Supported by the Board of Directors at Its Combined General Meeting | 290 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to the development... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,040 | -3,10 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
| ABBVIE | 183,00 | -3,20 % | AbbVie-Aktie mit Kursgewinnen (193,3778 €) | An der US-amerikanischen Börse liegt die AbbVie-Aktie gegenwärtig im Plus. Das Wertpapier notiert zur Stunde bei 209,14 US-Dollar. Im US-amerikanischen Wertpapierhandel hat sich heute die AbbVie-Aktie... ► Artikel lesen | |
| HAEMATO | 12,800 | 0,00 % | EQS-Adhoc: M1 Kliniken AG: HAEMATO AG prüft Angebot für den Verkauf ihres Handelssegments | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Beteiligung/Unternehmensbeteiligung/Sonstiges
M1 Kliniken AG: HAEMATO AG prüft Angebot für den Verkauf ihres Handelssegments
01.04.2025 / 17:13... ► Artikel lesen | |
| HALEON | 4,747 | +1,43 % | Haleon PLC - Total Voting Rights and Capital | ||
| LIGAND PHARMACEUTICALS | 95,50 | 0,00 % | ROUNDUP: Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook | WASHINGTON (dpa-AFX) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,210 | -5,76 % | Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program | Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| ROYALTY PHARMA | 28,330 | -1,70 % | UBS maintains neutral Royalty Pharma stock with $33 target | ||
| TG THERAPEUTICS | 35,700 | -2,79 % | IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche | ||
| DR REDDYS | 11,700 | -2,50 % | Bio-Thera And Dr. Reddy's Partner To Launch Stelara And Simponi Biosimilars In Southeast Asia | NEW DELHI (dpa-AFX) - Bio-Thera Solutions and Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (RDY), announced that they have reached commercialization... ► Artikel lesen | |
| EISAI | 24,300 | -0,49 % | Dividendenbekanntmachungen (28.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC ADR US00108N1000 0,3716 USD 0,3442 EUR ACOM CO LTD JP3108600002 7 JPY 0,0429 EUR ADVANEX INC JP3213400009 20... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 52,00 | -6,31 % | Verona Pharma plc: Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS | RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,051 | -9,73 % | Betterlife Pharma Inc (2): Betterlife Pharma appoints Beaudry as corporate adviser | ||
| ENTOURAGE HEALTH | 0,001 | 0,00 % | Entourage Health Corp. Announces Shareholder Approval of Going-Private Transaction | TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the "Company" or "Entourage") is pleased to announce that the shareholders of the Company... ► Artikel lesen | |
| IGC PHARMA | 0,260 | -1,52 % | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health | POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation... ► Artikel lesen | |
| KYOWA KIRIN | 13,000 | -1,52 % | Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis | Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.
